124 related articles for article (PubMed ID: 2256193)
1. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
Kolarić K; Tomek R
Tumori; 1990 Oct; 76(5):472-5. PubMed ID: 2256193
[TBL] [Abstract][Full Text] [Related]
2. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
Kolarić K; Vukas D; Potrebica V
Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
[TBL] [Abstract][Full Text] [Related]
3. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
Kolarić K; Roth A; Vukas D; Cervek J
Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report.
Kolarić K; Vukas D; Roth A; Potrebica V; Cervek J; Cerar O
Tumori; 1985 Apr; 71(2):159-65. PubMed ID: 3890307
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Legha SS; Ajani JA; Blumenschein GR; Hortobagyi GN; Buzdar AU
Cancer; 1984 May; 53(9):1836-40. PubMed ID: 6231092
[TBL] [Abstract][Full Text] [Related]
8. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
9. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
11. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Hirshaut Y; Kesselheim H
Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer.
Verusio C; Bajetta E; Ferrari L; Bartoli C; Valagussa P; Bonadonna G
Am J Clin Oncol; 1988 Aug; 11(4):435-9. PubMed ID: 3407621
[TBL] [Abstract][Full Text] [Related]
14. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
15. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
17. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Lichtman SM; Budman D; Bosworth H; Allen S; Schulman P; Weiselberg L; Weiss R; Lehrman D; Vinciguerra V
Am J Clin Oncol; 1991 Aug; 14(4):317-21. PubMed ID: 1907428
[TBL] [Abstract][Full Text] [Related]
19. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
[No Abstract] [Full Text] [Related]
20. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
